955 Chesterbrook Boulevard
Suite 110
Chesterbrook, PA 19087
United States
610 354 8840
https://www.trevena.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 35
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Ms. Carrie L. Bourdow | President, CEO & Chairman | 1M | N/D | 1963 |
Mr. Barry Shin | Executive VP, COO & CFO | 670,02k | N/D | 1973 |
Dr. Mark A. Demitrack M.D. | Senior VP & Chief Medical Officer | 690,32k | N/D | 1959 |
Dr. Howard A. Rockman M.D. | Scientific Founder, Consultant and Member of Scientific Advisory Board | N/D | N/D | N/D |
Mr. Joel Solomon | VP, General Counsel & Chief Compliance Officer | N/D | N/D | N/D |
Mr. Michael Catalano | Vice President of Marketing | N/D | N/D | N/D |
Mr. Robert T. Yoder | Senior VP, Chief Business Officer & Head of Commercial Operations | 490,64k | N/D | 1966 |
Ms. Patricia M. Drake | Senior VP & Chief Commercial Officer | N/D | N/D | 1966 |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.
L'ISS Governance QualityScore di Trevena, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.